Lilly’s triple agonist retatrutide outmuscles Ozempic on weight loss, delivering greater weight reduction and blood sugar control in trials.
Cancer drugs are facing new price controls in India, but unchanged prices for several patented therapies raise questions about affordability and patients' actual treatment expenses.
GSK share price falls despite a third quarter earnings beat as weaker vaccine sales, Shingrix and Arexvy disappoint investors.
Artiva's AlloNK discontinuation raises questions about autoimmune cell therapy safety, fludarabine toxicity, and whether early clinical responses can deliver lasting benefits in autoimmune disease treatment.
Cosmetic claims have come under regulatory scrutiny after DCGI cancelled FatX Solution's import registration, highlighting the compliance risks of online product descriptions and approved labels.
The Lancet ranking reveals India’s heat blind spot as infants and older adults face rising heatwave exposure and inadequate targeted protection.
Cipla’s respiratory muscle drives US growth, but can its commercial network deliver success with a Keytruda biosimilar in oncology?
Ayushman Bharat's expanding health-data infrastructure could help Indian pharmaceutical researchers evaluate treatment outcomes, strengthen drug safety monitoring and improve real-world evidence.
Cipla’s Rs 423 crore R&D investment signals a long-term growth bet despite a 35% profit decline and weaker US sales.
TROP2 ADC sac-TMT extends survival in advanced endometrial cancer, offering a potential new treatment option after chemotherapy and immunotherapy failure in a late-stage clinical trial.
.jpg)
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")
